Ajax Therapeutics

Ajax Therapeutics is pursuing a unique and selective approach to develop new therapies targeting key cytokine signaling pathways that drive hematologic malignancies. By combining the industry's most advanced computational drug discovery and protein structure platforms provided by our founding partner, Schrödinger, Inc., with the deep cancer and structural biology insights of our founding scientists, our goal is to discover and develop more precisely designed treatments to address the needs of patients with serious hematologic malignancies. We see ourselves as warriors operating at the intersection of computational chemistry and cancer biology, and we are committed to creating drugs that have a transformative impact on the lives of cancer patients.